Singapore, Aug. 5 -- AsymBio, a China-based biologics-focused Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Asymchem Group, has announced a total capital injection of RMB 1.2397 billion (approximately $184 million) into AsymBio by Asymchem Group, Hillhouse Qirui and other investors.

Upon completion of the capital increase, Asymchem Group's shareholding in AsymBio will increase to 83.4965%. The transaction reflects strong confidence in AsymBio's differentiated CDMO strategy and its long-term potential to support global pharmaceutical and biotechnology companies advancing complex biologics programmes.

Of the total capital injection, Asymchem Group will contribute RMB 1.05 billion (approximately $156 millio...